Jobs / United States / Sanofi US Services INC
E4A Systemic Mastocytosis/Emerging Indication HEOR Strategy Specialist
Sanofi US Services INC · 🇺🇸 2 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 29 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Sanofi US Services INC
The US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 29 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Sanofi US Services INC →
About the role
Job title: E4A Systemic Mastocytosis/Emerging Indication HEOR Strategy Specialist Location: Cambridge, MA About the Job HEVA's mission is to conduct, communicate, and translate evidence to demonstrate the value of Sanofi's products and support optimal access and treatment outcomes for patients. HEVA Vision, Mission, and Values We are one bold HEOR team leveraging innovative HEOR to transform patient care and access. As HEOR experts, we lead the generation and dissemination of robust, business-relevant evidence to demonstrate value and drive access to medicines. The HEVA organization is driven by five core values that define how we work and deliver impact. We operate as One Team, partnering without boundaries while pursuing a Bold Purpose through ambitious, measurable goals. Grounded in Scientific Excellence with Relevance and deep technical expertise, we embrace Innovation in Action to transform how we research and deliver Impact for People, creating meaningful outcomes for patients, the healthcare ecosystem, and our colleagues who make it all possible. Join the team transforming care for people with immune challenges, rare diseases, cancers, and neurological conditions. In Specialty Care, you’ll help deliver breakthrough treatments that bring hope to patients with some of the highest unmet needs. About Sanofi We’re an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Our deep understanding of the immune system – and innovative pipeline – enables us to invent medicines and vaccines that treat and protect millions of people around the world. Together, we chase the miracles of science to improve people’s lives. Main Responsibilities This role will lead US‑focused Health Economic and Outcomes Research activities for AYVAKIT® in Systemic Mastocytosis and emerging pipeline assets within the US Rare/Oncology HEVA team, providing US insights and executional leadership while remaining aligned to — but not accountable for — global HEVA strategy. • Lead the design and execution of US-focused HEOR for AYVAKIT® (avapritinib) in Systemic Mastocytosis and assigned emerging assets — including economic modelling, database analysis, observational research, RWE studies, systematic literature review, evidence synthesis, and AMCP dossier development — setting US evidence generation priorities and incorporating them into broader Sanofi planning documents such as the Integrated Evidence Generation Plan (IEGP); operate with medium independence for strategic work and high independence for tactical execution, consistent with L3-2 expectations. • Translate HEVA evidence into US business and policy impact by driving payer engagement, value positioning, and access strategies for AYVAKIT® in the US marketplace; understand and address US payer evidence requirements across managed care, specialty pharmacy, and rare disease payer dynamics; and support the development of compliant and impactful US evidence dissemination pathways (e.g., HCEI, PIE, CFL) including payer dossiers, field materials, and publications. • Operate as part of a multi-functional US brand team responsible for designing research programs to meet the evidentiary standards of US reimbursement authorities and third-party payers; provide recommendations to ensure clinical and real-world evidence programs support US payer differentiation and value demonstration; and contribute to cross-functional US planning processes including brand planning, lifecycle management, and launch readiness for AYVAKIT® and pipeline assets. • Serve as the US HEVA representative within the broader global HEVA team, ensuring the US perspective is well represented in global IEGPs, clinical development programs, and market access s